Literature DB >> 34748628

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.

Simona Pagliuca1,2, Carmelo Gurnari1,3, Hassan Awada1, Ashwin Kishtagari1, Sunisa Kongkiatkamon1, Laila Terkawi1, Misam Zawit1, Yihong Guan1, Thomas LaFramboise4, Babal K Jha1, Bhumika J Patel5, Betty K Hamilton6, Navneet S Majhail6, Sofie Lundgren7,8, Satu Mustjoki7,8,9, Yogen Saunthararajah1, Valeria Visconte1, Timothy A Chan10, Chao-Yie Yang11, Tobias L Lenz12,13, Jaroslaw P Maciejewski1.   

Abstract

Idiopathic aplastic anemia (IAA) is a rare autoimmune bone marrow failure (BMF) disorder initiated by a human leukocyte antigen (HLA)-restricted T-cell response to unknown antigens. As in other autoimmune disorders, the predilection for certain HLA profiles seems to represent an etiologic factor; however, the structure-function patterns involved in the self-presentation in this disease remain unclear. Herein, we analyzed the molecular landscape of HLA complexes of a cohort of 300 IAA patients and almost 3000 healthy and disease controls by deeply dissecting their genotypic configurations, functional divergence, self-antigen binding capabilities, and T-cell receptor (TCR) repertoire specificities. Specifically, analysis of the evolutionary divergence of HLA genotypes (HED) showed that IAA patients carried class II HLA molecules whose antigen-binding sites were characterized by a high level of structural homology, only partially explained by specific risk allele profiles. This pattern implies reduced HLA binding capabilities, confirmed by binding analysis of hematopoietic stem cell (HSC)-derived self-peptides. IAA phenotype was associated with the enrichment in a few amino acids at specific positions within the peptide-binding groove of DRB1 molecules, affecting the interface HLA-antigen-TCR β and potentially constituting the basis of T-cell dysfunction and autoreactivity. When analyzing associations with clinical outcomes, low HED was associated with risk of malignant progression and worse survival, underlying reduced tumor surveillance in clearing potential neoantigens derived from mechanisms of clonal hematopoiesis. Our data shed light on the immunogenetic risk associated with IAA etiology and clonal evolution and on general pathophysiological mechanisms potentially involved in other autoimmune disorders.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34748628      PMCID: PMC8718627          DOI: 10.1182/blood.2021012900

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  70 in total

1.  Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia.

Authors:  Takamasa Katagiri; Aiko Sato-Otsubo; Koichi Kashiwase; Satoko Morishima; Yusuke Sato; Yuka Mori; Motohiro Kato; Masashi Sanada; Yasuo Morishima; Kohei Hosokawa; Yumi Sasaki; Shigeki Ohtake; Seishi Ogawa; Shinji Nakao
Journal:  Blood       Date:  2011-09-30       Impact factor: 22.113

Review 2.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 3.  Ancestral polymorphisms of MHC class II genes: divergent allele advantage.

Authors:  E K Wakeland; S Boehme; J X She; C C Lu; R A McIndoe; I Cheng; Y Ye; W K Potts
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

4.  Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia.

Authors:  Chiharu Sugimori; Hirohito Yamazaki; Xingmin Feng; Kanako Mochizuki; Yukio Kondo; Akiyoshi Takami; Tatsuya Chuhjo; Akinori Kimura; Masanao Teramura; Hideaki Mizoguchi; Mitsuhiro Omine; Shinji Nakao
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

5.  Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia.

Authors:  Tatsuya Imi; Takamasa Katagiri; Kazuyoshi Hosomichi; Yoshitaka Zaimoku; Viet Hoang Nguyen; Noriharu Nakagawa; Atsushi Tajima; Tetsuichi Yoshizato; Seishi Ogawa; Shinji Nakao
Journal:  Blood Adv       Date:  2018-05-08

6.  Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Authors:  Katarina Tengvall; Jesse Huang; Cecilia Hellström; Patrick Kammer; Martin Biström; Burcu Ayoglu; Izaura Lima Bomfim; Pernilla Stridh; Julia Butt; Nicole Brenner; Angelika Michel; Karin Lundberg; Leonid Padyukov; Ingrid E Lundberg; Elisabet Svenungsson; Ingemar Ernberg; Sigurgeir Olafsson; Alexander T Dilthey; Jan Hillert; Lars Alfredsson; Peter Sundström; Peter Nilsson; Tim Waterboer; Tomas Olsson; Ingrid Kockum
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

7.  Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia.

Authors:  S Nakao; H Takamatsu; T Chuhjo; M Ueda; S Shiobara; T Matsuda; T Kaneshige; H Mizoguchi
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

Review 8.  Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.

Authors:  Spencer E Brightman; Martin S Naradikian; Aaron M Miller; Stephen P Schoenberger
Journal:  J Leukoc Biol       Date:  2020-03-14       Impact factor: 4.962

9.  Genetic and environmental determinants of human TCR repertoire diversity.

Authors:  Chirag Krishna; Diego Chowell; Mithat Gönen; Yuval Elhanati; Timothy A Chan
Journal:  Immun Ageing       Date:  2020-09-04       Impact factor: 6.400

10.  A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia.

Authors:  Hiroki Mizumaki; Kazuyoshi Hosomichi; Kohei Hosokawa; Takeshi Yoroidaka; Tatsuya Imi; Yoshitaka Zaimoku; Takamasa Katagiri; Mai Anh Thi Nguyen; Dung Cao Tran; Mahmoud Ibrahim Yousef Elbadry; Kazuhisa Chonabayashi; Yoshinori Yoshida; Hiroyuki Takamatsu; Tatsuhiko Ozawa; Fumihiro Azuma; Hiroyuki Kishi; Yoichi Fujii; Seishi Ogawa; Atsushi Tajima; Shinji Nakao
Journal:  Haematologica       Date:  2021-06-01       Impact factor: 9.941

View more
  6 in total

1.  Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.

Authors:  Emma M Groarke; Bhavisha A Patel; Ruba Shalhoub; Fernanda Gutierrez-Rodrigues; Parth Desai; Harshraj Leuva; Yoshitaka Zaimoku; Casey Paton; Nina Spitofsky; Jennifer Lotter; Olga Rios; Richard W Childs; David J Young; Alina Dulau-Florea; Cynthia E Dunbar; Katherine R Calvo; Colin O Wu; Neal S Young
Journal:  Leukemia       Date:  2022-07-27       Impact factor: 12.883

2.  Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15.

Authors:  Noriaki Tsuji; Kohei Hosokawa; Ryota Urushihara; Mikoto Tanabe; Takamasa Katagiri; Tatsuhiko Ozawa; Hiroyuki Takamatsu; Ken Ishiyama; Hirohito Yamazaki; Hiroyuki Kishi; Seishi Ogawa; Shinji Nakao
Journal:  Leukemia       Date:  2022-04-26       Impact factor: 12.883

Review 3.  Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy.

Authors:  Ahmed Halima; Winston Vuong; Timothy A Chan
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

4.  Diagnostic Value of a Protocolized In-Depth Evaluation of Pediatric Bone Marrow Failure: A Multi-Center Prospective Cohort Study.

Authors:  Khaled Atmar; Claudia A L Ruivenkamp; Louise Hooimeijer; Esther A R Nibbeling; Corien L Eckhardt; Elise J Huisman; Arjan C Lankester; Marije Bartels; Gijs W E Santen; Frans J Smiers; Mirjam van der Burg; Alexander B Mohseny
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

Review 5.  Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond.

Authors:  Simona Pagliuca; Carmelo Gurnari; Marie Thérèse Rubio; Valeria Visconte; Tobias L Lenz
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

6.  HLA-B evolutionary divergence is associated with outcomes after SARS-CoV-2 infection.

Authors:  Patricia V Hernandez; Brian Duffy; Karl Hock; Christopher Farnsworth; Emily Schindler; Chang Liu
Journal:  Hum Immunol       Date:  2022-09-12       Impact factor: 2.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.